Targeted therapy in biliary tract cancer: 2009 Update

Future Oncology

Volumn 5, Issue 10, 2009, Pages 1675-1684

  Tonini, Giuseppe ^a   Virzì, Vladimir ^a   Fratto, Maria Elisabetta ^a   Vincenzi, Bruno ^a   Santini, Daniele ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Anti EGFR therapy; Antiangiogenic therapy; Biliary tract cancer; Molecular features; Prognostic factors; Targeted therapy

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CETUXIMAB; CISPLATIN; DEFOROLIMUS; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; K RAS PROTEIN; LAPATINIB; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; OXALIPLATIN; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; SORAFENIB; TEMSIROLIMUS; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN E;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; EMBOLISM; ENZYME INHIBITION; GALLBLADDER CARCINOMA; HAND FOOT SYNDROME; HUMAN; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOSIS; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 75149140628     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.130     Document Type: Review

References (78)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin. Liver Dis. 24, 115-125 (2004).
3. Furuse J, Takada T, Miyazaki M et al.: Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J. Hepatobiliary Pancreat. Surg. 15, 55-62 (2008). ■ Comprehensive guidelines regarding the management of patients with biliary tract cancer.
4. Grove MK, Hermann RE, Vogt DP, Broughan TA: Role of radiation after operative palliation in cancer of the proximal bile ducts. Am. J. Surg. 161, 454-458 (1991).
5. Hezel FA, Zhu XA: Systemic therapy for biliary tract cancer. Oncologist 13, 415-423 (2008). ■■ A thorough review about the different treatments for biliary tract cancer patients.
6. Tonini G, Fratto M:E, Vincenzi B, Santini D: Classification of biliary tract cancer (BTC): evaluation of all entities. Ann. Oncol. 20, 6 (2009). ■ An interesting letter that underlines the importance of a correct classification of biliary tract cancer for prognosis and treatment strategy.
7. Yoshikawa D, Ojima H, Iwasaki M et al.: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br. J. Cancer 98(2), 418-425 (2008).
8. Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 319, 1-11 (2004).
9. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (2005).
10. Normanno N, Bianco C, Strizzi L et al.: The ErbB receptors and their ligands in cancer: an overview. Curr. Drug Targets 6, 243-257 (2005).
11. Linggi B, Carpenter G: ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 16, 649-656 (2006).
12. Rocha-Lima CM, Soares HP, Raez LE, Singal R: EGFR targeting of solid tumors. Cancer Control 14, 295-304 (2007).
13. Sangro B, Mazzollini G, Prieto J: Future therapies for hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 17, 515-521 (2005).
14. Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ: Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J. Hepatol. 41, 808-814 (2004).
15. Werneburg NW, Yoon JH, Higuchi H, Gores GJ: Bile acids activate EGF receptor via a TGF-a-dependent mechanism in human cholangiocyte cell lines. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G31-G36 (2003).
16. Nakazawa K, Dobashi Y, Suzuki S et al.: Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J. Pathol. 206, 356-365 (2005).
17. Leone F, Cavalloni G, Pignochino Y et al.: Somatic mutations of epidermal growth factor receptor in bile duct and gall bladder carcinoma. Clin. Cancer Res. 12(6), 1680-1685 (2006).
18. Tannapfel A, Benicke M, Katalinic A et al.: Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47(5), 721-727 (2000).
19. Suto T, Habano W, Sugai T et al.: Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer. J. Surg. Oncol. 73(3), 158-163 (2000).
20. Hidaka E, Yanagisawa A, Seki M, Takano K, Setoguchi T, Kato Y: High frequency of K-ras mutations in biliary duct carcinomas of cases with a long common channel in the papilla of Vater. Cancer Res. 60(3), 522-524 (2000).
21. Rashid A, Ueki T, Gao YT et al.: K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin. Cancer Res. 8(10), 3156-3163 (2002).
22. Ariyama H, Qin B, Baba E et al.: Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gall bladder adenocarcinoma cells. J. Cell Biochem. 97, 724-734 (2006).
23. Miyata H, Sasaki T, Kuwahara K, Serikawa M, Chayama K: The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines. Int. J. Oncol. 28, 915-921 (2006).
24. Zhang Z, Sirica AE: Simultaneous inhibition of ErbB1 and ErbB2 signaling significantly enhances the growth suppression of rat and human cholangiocarcinoma cell lines. FASEB J. 21, A71-A72 (2007).
25. Jimeno A, Rubio-Viqueira B, Amador ML et al.: Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res. 65, 3003-3010 (2005).
26. Sirica A: Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J. Gastroenterol. 14(46), 7033-7058 (2008).
27. Herberger B, Berger W, Puhalla H et al.: Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Mol. Cancer Ther. 8(6), 1547-1556 (2008).
28. Wiedmann M, Feisthammel J, Blüthner T et al.: Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 17(7), 783-795 (2006)
29. Yoshikawa D, Ojima H, Kokubu A et al.: Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signaling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br. J. Cancer 100(8), 1257-1266 (2009).
30. Carmeliet P: Angiogenesis in health and disease. Nat. Med. 9, 653-660 (2003).
31. Shibuya M: Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9, 225-230 (2006).
32. Benckert C, Jonas S, Cramer T et al.: Transforming growth factor b1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 63, 1083-1092 (2003).
33. Tang D, Nagano H, Yamamoto H, Wada H et al.: Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol. Rep. 15, 525-532 (2006).
34. Aishima S, Taguchi K, Sugimachi K et al.: The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma. Int. J. Surg. Pathol. 10, 47-56 (2002).
35. Guedj N, Zhan Q, Perigny MJ et al.: Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J. Hepatol. 51(1), 93-101 (2009).
36. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18 (2002).
37. Zhu AX: Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112, 250-259 (2008).
38. Drevs J, Siegert P, Medinger M et al.: Phase clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25, 3045-3054 (2007).
39. Aragon-Ching JB, Dahut WL: The role of angiogenesis inhibitors in prostate cancer. Cancer J. 14, 20-25 (2008).
40. Wedge SR, Kendrew J, Hennequin LF et al.: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389-4400 (2005).
41. Sachdev D, Yee D: Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 6, 1-12 (2007).
42. Zhang H, Yee D: The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opin. Investig. Drugs 13, 1569-1577 (2004).
43. Wang Z, Ruan YB, Guan Y, Liu SH: Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J. Gastroenterol. 9, 267-227 (2003).
44. Hofmann F, Garcia-Echeverria C: Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov. Today 10, 1041-1047 (2005).
45. Alvaro D, Barbaro B, Franchitto A et al.: Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am. J. Pathol. 169, 877-888 (2006).
46. Schmitz KJ, Lang H, Wohlschlaeger J et al.: AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J. Gastroenterol. 13, 6470-6477 (2007)
47. Duran I, Salazar R, Casanovas O et al.: New drug development in digestive neuroendocrine tumors. Ann. Oncol. 18, 1307-1313 (2007).
48. Yang L, Dan HC, Sun M et al.: Discovery of a small molecule Akt inhibitor with antitumor activity in cancer cells overexpressing Akt. Proc. Am. Assoc. Cancer Res. 45(Suppl.), 893 (2004).
49. Tsang CK, Qi H, Liu LF, Zheng XF: Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 12, 112-124 (2007).
50. Sawada T, Okada T, Kubota K: Rapamycin inhibits the growth of cholangiocarcinoma cells in vitro. J. Clin. Oncol. 25(Suppl. 18), 15153 (2007).
51. Herberger B, Puhalla H, Lehnert M et al.: Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin. Cancer Res. 13, 4795-4799 (2007).
52. Tannapfel A, Benicke M, Katalinic A et al.: Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47,
53. 721-727 (2000). 53. Tannapfel A, Weinans L, Geissler F et al.: Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig. Dis. Sci. 45, 317-324 (2000).
54. Tannapfel A, Sommerer F, Benicke M et al.: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52, 706-712 (2003).
55. Wilhelm SM, Carter C, Tang L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
56. Huether A, Höpfner M, Baradari V, Schuppan D, Scherubl H: Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem. Pharmacol. 73, 1308-1317 (2007).
57. Höpfner M, Baradari V, Huether A, Scherübl H: Growth inhibition of human cholangiocarcinoma by sorafenib-based mono- and combination treatment. FASEB J. 22, 1136-1139 (2008).
58. Baradari V, Hopfner M, Huether A, Schuppan D, Scherubl H: Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J. Gastroenterol. 13, 4458-4466 (2007).
59. Roccaro AM, Hideshima T, Richardson PG et al.: Bortezomib as an antitumor agent. Curr. Pharm. Biotechnol. 7, 441-448 (2006).
60. Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC: Proteasome inhibitors as therapeutics. Essays Biochem. 41, 205-218 (2005).
61. Schwartz R, Davidson T: Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology 18, 14-21 (2004).
62. Brignole C, Marimpietri D, Pastorino F et al.: Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J. Natl Cancer Inst. 98, 1142-1157 (2006).
63. Ustundag Y, Bronk SF, Gores GJ: Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. World J. Gastroenterol. 13, 851-857 (2007).
64. Philip PA, Mahoney MR, Allmer C et al.: Phase II study of erlotinib in patients with advanced biliary cancer. J. Clin. Oncol. 24, 3069-3074 (2006). ■ An important Phase II trial regarding erlotinib in bilary tract cancer.
65. Sprinzl MF, Schimanski CC, Moehler M et al.: Gemcitabine in combination with EGF-receptor antibody (cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer 6, 190 (2006).
66. Paule B, Bralet M, Herelle M et al.: Cetuximab plus gemcitabine/oxaliplatin (GEMOX) for patients with unresectable/ recurrent intrahepatic cholangiocarcinoma refractory to GEMOX. J. Clin. Oncol. 24(Suppl. 18), 14084 (2007).
67. Paule B, Herelle MO, Rage E et al.: Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72, 105-110 (2007).
68. Malka D, Trarbach T, Fartoux L et al.: A multicenter, randomized Phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim ana lysis of the BINGO trial. J. Clin. Oncol. 27, S15 (2009) (Abstract 4520). ■■ The first randomized trial regarding the activity of the combination between cetuximab and gemcitabine-oxaliplatin in biliary tract cancer.
69. Gruenberger B,Schueller J, Tamandl D et al.: K-ras status and response in patients with advanced or metastatic cholangiocarcinoma treated with cetuximab plus gemcitabine-oxaliplatin (GEMOX): a single center Phase II study. J. Clin. Oncol. 27, S15 (2009) (Abstract 4586).
70. Ramanathan RK, Belani CP, Singh DA et al.: Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J. Clin. Oncol. 24(Suppl.), S18 (2006) (Abstract 4010).
71. Tai CJ, Chiou HY, Wu CH, Pan S, Liu JD: Rapid resolution of liver metastasis from cholangiocarcinoma after bevacizumab with cisplatin and high-dose fluorouracil plus leucovorin. Onkologie 29, 179-180 (2006).
72. Clark JW, Meyerhardt JA, Sahani DV et al.: Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gall bladder cancers. J. Clin. Oncol. 25(Suppl.), S18 (2007) (Abstract 4625).
73. Zhu AX, Meyerhardt JA, Blaszkowsky LS et al.: Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX). J. Clin. Oncol. 27, S15 (2009) (Abstract 4578).
74. El-Khoueiry AB, Rankin C, Lenz HJ, Philip P, Rivkin SE Blanke CD: SWOG 0514: a Phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gall bladder cancer or cholangiocarcinomas. J. Clin. Oncol. 25(Suppl. 20), 4639 (2007). ■ The first evidence of the activity of sorafenib as a single agent in patients with biliary tract cancer.
75. Sprenger K, Moehler M, Kettner E et al.: Preliminary results of a multicenter Phase II study of imatinib and fluorouracil/leucovorin (FU/LV) in patients with unresectable or metastatic gall bladder or biliary tract cancer. J. Clin. Oncol. 27(Suppl.) (2009) (Abstract E15502).
76. Messersmith WA, Baker SD, Lassiter L et al.: Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin. Cancer Res. 12, 1270-1275 (2006).
77. Costello MR, Meropol NJ, Denlinger CS et al.: A Phase II trial of the proteasome inhibitor bortezomib in patients with recurrent or metastatic adenocarcinoma of the bile duct or gall bladder (NCI #6135). J. Clin. Oncol. 27(Suppl.) (2009) (Abstract E15605).
78. Valle JW, Wasan HS, Palmer DD: Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter, randomized Phase III trial (the UK ABC-02 trial). J. Clin. Oncol. 27, S15 (2009) (Abstract 4503).